Перейти к содержанию

Bio-rad Laboratories, Inc. (BIO) stock: revenue, earnings & dividend

Bio-rad Laboratories, Inc. (BIO, NYSE): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener BIO · NYSE Medizintechnik & Messgeräte US-CA

Key figures

Fiscal year
2025
Revenue
2.58 bn $
Revenue growth
0.7 %
Revenue growth 5y (p.a.)
0.3 %
Net income
760 m $
Net margin
29.4 %
Operating margin
1.8 %
Earnings per share (diluted)
27.85 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
10.6 bn $
Equity
7.45 bn $
Equity ratio
70.5 %
Return on equity
10.2 %
Cash
530 m $
Operating cash flow
532 m $
Free cash flow
375 m $
Shares outstanding
–

History

Revenue by fiscal year

2016 2.07 bn $
2017 2.16 bn $
2018 2.29 bn $
2019 2.31 bn $
2020 2.55 bn $
2021 2.92 bn $
2022 2.8 bn $
2023 2.67 bn $
2024 2.57 bn $
2025 2.58 bn $

Net income by fiscal year

2016 26 m $
2017 122 m $
2018 366 m $
2019 1.76 bn $
2020 3.81 bn $
2021 4.25 bn $
2022 -3.63 bn $
2023 -637.3 m $
2024 -1.84 bn $
2025 760 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20252.58 bn $760 m $27.85 $–532 m $
20242.57 bn $-1.84 bn $-65.36 $–455 m $
20232.67 bn $-637.3 m $-21.82 $–375 m $
20222.8 bn $-3.63 bn $-121.79 $–194 m $
20212.92 bn $4.25 bn $140.83 $–669 m $
20202.55 bn $3.81 bn $126.47 $–585 m $
20192.31 bn $1.76 bn $58.27 $–458 m $
20182.29 bn $366 m $12.10 $–285 m $
20172.16 bn $122 m $4.07 $–104 m $
20162.07 bn $26 m $0.88 $–216 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)